Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 28, 2026
DataAggregated Company Financials
Companies147
  • 7D3.1%
  • 3M-6.4%
  • 1Y-4.9%
  • YTD-5.7%

Over the last 7 days, the Healthcare industry has risen 2.5%, driven by gains from Swedish Orphan Biovitrum of 7.3%. In the past year, the industry is down 4.6%. As for the next few years, earnings are expected to grow by 25% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 28 Mar 2026SEK 548.0bSEK 228.9b-SEK 2,600,488,471.3429.3x-210.7x2.4x
Mon, 23 Feb 2026SEK 569.3bSEK 229.3b-SEK 1,647,883,826.1131.3x-345.5x2.5x
Wed, 21 Jan 2026SEK 587.6bSEK 230.1bSEK 3.7b41.1x160.2x2.6x
Fri, 19 Dec 2025SEK 574.0bSEK 230.7bSEK 3.6b41.1x157.4x2.5x
Sun, 16 Nov 2025SEK 603.6bSEK 230.5bSEK 2.9b44.4x205.9x2.6x
Tue, 14 Oct 2025SEK 599.2bSEK 227.1bSEK 6.7b43.1x89.7x2.6x
Thu, 11 Sep 2025SEK 610.7bSEK 227.0bSEK 6.6b44.7x92.4x2.7x
Sat, 09 Aug 2025SEK 605.3bSEK 226.8bSEK 6.8b45.4x88.5x2.7x
Mon, 07 Jul 2025SEK 629.2bSEK 227.1bSEK 6.0b44.6x104.5x2.8x
Wed, 04 Jun 2025SEK 605.0bSEK 226.4bSEK 5.8b43.1x103.5x2.7x
Fri, 02 May 2025SEK 593.2bSEK 223.8bSEK 4.9b37x121x2.7x
Sun, 30 Mar 2025SEK 571.6bSEK 220.9bSEK 5.4b36.2x105.8x2.6x
Tue, 25 Feb 2025SEK 587.5bSEK 206.1bSEK 4.4b36.9x133.5x2.9x
Thu, 23 Jan 2025SEK 589.1bSEK 202.6b-SEK 2,463,557,065.8641.7x-239.1x2.9x
Sat, 21 Dec 2024SEK 575.5bSEK 202.6b-SEK 2,503,131,958.0438.8x-229.9x2.8x
Mon, 18 Nov 2024SEK 509.8bSEK 199.9b-SEK 2,849,689,856.4537.4x-178.9x2.5x
Wed, 16 Oct 2024SEK 595.5bSEK 198.5b-SEK 2,314,588,459.1639.4x-257.3x3x
Fri, 13 Sep 2024SEK 617.3bSEK 200.2b-SEK 2,805,394,669.4540.9x-220x3.1x
Sun, 11 Aug 2024SEK 573.5bSEK 199.5b-SEK 2,394,284,457.5740.8x-239.5x2.9x
Tue, 09 Jul 2024SEK 570.9bSEK 195.9b-SEK 3,195,547,338.4438.5x-178.6x2.9x
Thu, 06 Jun 2024SEK 562.7bSEK 195.6b-SEK 2,827,643,502.4641.1x-199x2.9x
Sat, 04 May 2024SEK 537.6bSEK 196.5b-SEK 3,179,876,922.4334.8x-169x2.7x
Mon, 01 Apr 2024SEK 527.7bSEK 192.9b-SEK 3,674,506,154.3846x-143.6x2.7x
Wed, 28 Feb 2024SEK 506.0bSEK 191.8b-SEK 3,869,646,597.7449.1x-130.8x2.6x
Fri, 26 Jan 2024SEK 549.7bSEK 191.6b-SEK 899,735,716.0050.4x-610.9x2.9x
Sun, 24 Dec 2023SEK 534.3bSEK 191.0b-SEK 960,233,351.0047.8x-556.5x2.8x
Tue, 21 Nov 2023SEK 493.0bSEK 190.1b-SEK 1,226,384,668.0049.9x-402x2.6x
Thu, 19 Oct 2023SEK 427.4bSEK 185.1b-SEK 1,931,014,806.0031.9x-221.3x2.3x
Sat, 16 Sep 2023SEK 454.9bSEK 185.7b-SEK 2,024,682,673.0036.5x-224.7x2.4x
Mon, 14 Aug 2023SEK 474.6bSEK 184.3b-SEK 1,014,174,020.0041.7x-468x2.6x
Wed, 12 Jul 2023SEK 474.9bSEK 179.2b-SEK 787,767,930.0044.1x-602.9x2.7x
Fri, 09 Jun 2023SEK 510.2bSEK 179.0b-SEK 714,848,226.0041.5x-713.8x2.9x
Sun, 07 May 2023SEK 530.4bSEK 176.7b-SEK 667,620,231.0043x-794.5x3x
Tue, 04 Apr 2023SEK 489.1bSEK 172.5b-SEK 1,401,694,483.0035.5x-348.9x2.8x
Price to Earnings Ratio

-348.9x


Total Market Cap: SEK 489.1bTotal Earnings: -SEK 1,401,694,483.00Total Revenue: SEK 172.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -164.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.097%
Healthcare3.06%
Biotech5.94%
Medical Equipment2.60%
Healthcare Services1.77%
Pharma0.43%
Healthtech-1.17%
Life Sciences-1.35%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 385.607.3%
+SEK 9.1b		32.1%PE278.8x
ASKER Asker Healthcare GroupSEK 68.367.2%
+SEK 1.8b		-16.6%PE56.9x
XVIVO Xvivo PerfusionSEK 222.8021.7%
+SEK 1.3b		-25.6%PE278.9x
GETI B GetingeSEK 184.502.2%
+SEK 1.1b		-16.7%PE22.3x
VIMIAN Vimian GroupSEK 27.286.9%
+SEK 931.5m		-34.1%PE42.3x

Latest News

SOBI
SEK 385.60
Swedish Orphan Biovitrum
7D
7.3%
1Y
32.1%
GETI B
SEK 184.50
Getinge
7D
2.2%
1Y
-16.7%
MAGLE
SEK 3.96
Magle Chemoswed Holding
7D
-52.0%
1Y
-86.8%
ASKER
SEK 68.36
Asker Healthcare Group
7D
7.2%
1Y
-16.6%
FLUO
SEK 38.00
FluoGuide
7D
-12.8%
1Y
-0.7%
ALIF B
SEK 134.60
AddLife
7D
-2.0%
1Y
-8.6%

ALIF B: Higher Margin Outlook And Dividend Policy Will Support Future Upside

Analysts have trimmed their price target for AddLife from SEK191.50 to SEK187.50, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E levels. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex date on May 7, 2026, a record date on May 8, 2026, and a payment date on May 13, 2026 (Key Developments).
CURAS
DKK 14.80
Curasight
7D
-6.3%
1Y
87.3%
BIOA B
SEK 315.00
BioArctic
7D
2.9%
1Y
64.9%

BIOA B: Future Earnings Will Depend On High China Access Risk

Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.
XVIVO
SEK 222.80
Xvivo Perfusion
7D
21.7%
1Y
-25.6%

XVIVO: Higher Margins And Discount Assumptions Will Support Future Upside Potential

Analysts have modestly reduced their price target for Xvivo Perfusion to SEK245. This reflects slightly higher discount rate assumptions alongside small adjustments to revenue growth, profit margin, and future P/E expectations.
BONEX
SEK 186.30
Bonesupport Holding
7D
5.6%
1Y
-37.8%

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
MCOV B
SEK 185.20
Medicover
7D
-2.0%
1Y
-4.3%

MCOV B: Dividend Policy And 2028 Revenue Ambition Will Drive Future Upside

Analysts have trimmed their Medicover price target from SEK 325 to SEK 307 as updates to fair value, discount rate, revenue growth, profit margin assumptions and expected future P/E filter through their models. What's in the News The board proposes a dividend of SEK 0.20 per share for the 2025 financial year, up from SEK 0.15, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
VIMIAN
SEK 27.28
Vimian Group
7D
6.9%
1Y
-34.1%
SECT B
SEK 218.60
Sectra
7D
-1.5%
1Y
-11.6%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
EKTA B
SEK 53.80
Elekta
7D
-4.4%
1Y
-0.4%

EKTA B: Rising Margin Outlook And New Clearance Will Support Medium Term Upside

Analysts have nudged their price targets for Elekta higher, with one recent move taking the target to SEK 60 from SEK 49. This reflects updated views on fair value, discount rates, profit margins and future P/E assumptions.
VITR
SEK 92.00
Vitrolife
7D
4.6%
1Y
-44.5%
DICOT
SEK 0.39
Dicot Pharma
7D
-10.3%
1Y
25.6%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?